Acetylisovaleryltylosin tartrate injection and preparation method thereof
Through the aqueous dispersion system and liposome technology, combined with tyvonectin, myristoyl phosphatidate choline, cholesterol and buffer, the problems of low bioavailability and high tissue irritation of tyvonectin injection are solved. Highly efficient and low-stimulation injection preparation is achieved, extending the half-life of the drug elimination and improving the therapeutic effect.
Patent Information
- Application Number
- CN202311618730.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-30
- Publication Date
- 2024-11-26
AI Technical Summary
The existing tyvanectin injections have problems with low bioavailability and high tissue irritation, especially the injection resistance caused by oily solvents and the formation of intramuscular mass, which affects animal health and drug effect.
Using the aqueous dispersion system and liposome dispersion process, the combination of tyvanectin, myristoyl phosphatidate choline, cholesterol and buffer solution can avoid the use of organic solvents and oily solvents, and use ultrasonic and dialysis technology to prepare sterile injections to reduce injection resistance and extend the half-life of drug elimination.
The high bioavailability and low irritation of tyvonectin injection have been achieved, the injection resistance is reduced, the half-life of the drug is extended, and the purpose of one-time drug administration and long-term protection is achieved.
Smart Images

Figure CN119015219A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of veterinary chemical preparations, and particularly relates to a tyvalocin injection and a preparation method thereof. Background Art
[0002] Tylosin is a macrolide antibiotic for animals. It is a derivative of tylosin. It is obtained by acetylation or isovalerylation of the hydroxyl groups at two positions, which significantly improves the antibacterial activity of the drug in vivo and has a very good effect on the treatment of infections caused by macrolide-resistant strains. Tylosin has a broad antibacterial spectrum, high antibacterial activity, and low toxic and side effects. It is commonly used in the clinic to treat respiratory and digestive tract diseases.
[0003] At present, there are two dosage forms of tyvalosin developed at home and abroad: premix and powder. The premix is used for pigs, and the powder can be dissolved in water and is suitable for chickens. Both are dosage forms for oral administration. However, studies have shown that P-glycoprotein (P-gp) in animals has an effect on the absorption of tyvalosin and reduces its bioavailability after oral administration. Therefore, this field needs to consider the development of parenteral preparations to avoid biological waste caused by excretion after intestinal absorption.
[0004] Patent CN102119921A discloses a tyvalosin injection for pigs and its preparation method, which is mainly composed of 20% tyvalosin tartrate, 20-35% propylene glycol, 10-15% N,N-diformyl acetamide, 2-4% benzyl alcohol, and 0.1-1% di-tert-butyl paracresol. The invention prolongs the elimination half-life of the drug in the animal body, but its components contain organic solvents, which will cause greater stimulation to the animal body tissue. Another invention patent CN108403631A discloses the use of highly lipophilic oil as a dispersant to slow down the dissolution of the drug from the oily solvent to achieve slow release, thereby achieving the purpose of prolonging the drug action time. However, when the oily solvent is injected, the resistance is large and the needle permeability is poor. After injection, a mass will form in the intramuscular or subcutaneous tissue, causing pain in the animal body, while affecting the growth of surrounding tissues, resulting in a waste of carcass dissection.
[0005] Therefore, it is necessary to develop a tyvalocin injection with high bioavailability and low irritation in the art. Summary of the invention
[0006] The present invention aims to solve the problems in the prior art and provide a tyvalosin injection with high bioavailability and a preparation method thereof. The present invention adopts an aqueous dispersion system to avoid the stimulation of organic solvents and the influence of long-term massing of oily solvents on tissues. At the same time, the injection resistance is small and it is convenient for clinical use. Through the liposome dispersion process technology, the elimination half-life is extended to achieve the purpose of one-time administration and long-term protection.
[0007] To achieve the above purpose, the specific technical solution of the present invention is as follows:
[0008] In a first aspect, the present invention provides a tyvalosin injection, which is composed of the following components: tyvalosin, dimyristoylphosphatidylcholine, cholesterol, and a buffer.
[0009] The mass ratio of tyvalosin, dimyristoylphosphatidylcholine and cholesterol in the tyvalosin injection is (18-22):(10-15):(3-8).
[0010] Preferably, the mass ratio of tyvalosin, dimyristoylphosphatidylcholine and cholesterol in the tyvalosin injection is 20:13:5.
[0011] Preferably, the buffer is a phosphate buffer at pH 7.4 containing polyethylene glycol 400.
[0012] Preferably, the buffer further contains one or more of mannitol, glucose and lactose.
[0013] The volume of the polyethylene glycol 400 accounts for 8% to 12% of the volume of the buffer solution.
[0014] Preferably, the volume of polyethylene glycol 400 accounts for 10% of the volume of the buffer solution.
[0015] Preferably, the volume mass ratio of the buffer to mannitol, glucose and lactose is 100:(0-5):(0-5):(0-5) (ml:g:g:g).
[0016] The second aspect of the present invention provides a method for preparing tyvalocin injection, the steps of which are as follows:
[0017] (1) adding tyvalosin, dimyristoylphosphatidylcholine and cholesterol according to the formula amount into an organic solvent, dissolving and clarifying, and then evaporating under reduced pressure to obtain a lipid film A;
[0018] (2) adding an organic solvent to the lipid film A to redissolve the lipid film A, and adding a buffer to obtain solution B;
[0019] (3) Ultrasonicate solution B at 4°C to 8°C for 10 to 15 minutes to obtain solution C;
[0020] (4) Vacuum evaporation of liquid C until a gel material appears, and then continue vacuum evaporation for 10 to 15 minutes to obtain liquid D;
[0021] (5) Shake solution D on a mixer to obtain solution E;
[0022] (6) Continue to perform vacuum rotary evaporation on solution E for 5 to 10 minutes; use dialysis to remove the organic solvent with a buffer solution to obtain solution F;
[0023] (7) Liquid F was diluted to a certain volume with a buffer solution, homogenized twice at 300-400 bar in a high-pressure homogenizer, and then passed through a 0.2 μm polycarbonate membrane under high pressure to obtain a sterile tyvalocin injection solution.
[0024] The organic solvent in step (1) and step (2) is one or more of ethanol, isopropanol, ether, isopropyl ether, acetone and chloroform.
[0025] Preferably, the organic solvent in step (1) and step (2) is one or more of ethanol, isopropyl ether and acetone.
[0026] The volume mass ratio of the amount of the organic solvent added in step (1) and step (2) to tyvalocin is (120-180):(18-22) (ml:g).
[0027] Preferably, the volume mass ratio of the amount of the organic solvent added in step (1) and step (2) to tyvalocin is 150:20 (ml:g).
[0028] The temperature of the reduced pressure rotary evaporation in steps (1), (4) and (6) is 30 to 40°C.
[0029] The volume mass ratio of the amount of the buffer added in step (2) to tyvalocin is (25-35):(18-22) (ml:g).
[0030] Preferably, the volume-to-mass ratio of the amount of the buffer added in step (2) to tyvalocin is 30:20 (ml:g).
[0031] The volume mass ratio of the amount of buffer added to tyvalocin in step (6) is (45-55):(18-22) (ml:g).
[0032] Preferably, the volume mass ratio of the amount of buffer added to tyvalosin in step (6) is 50:20 (ml:g).
[0033] Beneficial effects:
[0034] 1. The tyvalocin injection prepared by the present invention has the characteristics of long elimination half-life, high bioavailability, and the advantages of one-time administration and long-term protection.
[0035] 2. The tyvalocin injection prepared by the present invention does not contain organic solvents, can avoid injection irritation, does not contain oily solvents, has low injection resistance, and is convenient for clinical use. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 The drug-time curve of tyvalocin injection. DETAILED DESCRIPTION
[0037] The above contents will be further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter being limited to the following embodiments. All technologies realized based on the contents of the present invention are within the scope.
[0038] Example 1
[0039] A tyvalosin injection, wherein each 100 ml of the tyvalosin injection contains the following components and dosages: 20 g of tyvalosin, 10 g of dimyristoylphosphatidylcholine, 3 g of cholesterol, and the remainder is a buffer solution.
[0040] The buffer is a phosphate buffer with a pH of 7.4 containing polyethylene glycol 400, and the buffer further contains mannitol, glucose and lactose. The volume of polyethylene glycol 400 accounts for 11% of the total volume of the buffer, and the volume mass ratio of the buffer to mannitol, glucose and lactose is 100:3:1:1 (ml:g:g:g).
[0041] The preparation method of the tyvalocin injection comprises the following steps:
[0042] (1) Add tyvalosin, dimyristoylphosphatidylcholine and cholesterol according to the formula amount into 120 ml of ethanol, dissolve and clarify, and evaporate under reduced pressure at 30° C. to obtain lipid film A;
[0043] (2) Add 120 ml of ethanol to lipid film A to redissolve lipid film A, and add 30 ml of buffer to obtain solution B;
[0044] (3) Ultrasonicate solution B at 4°C to 8°C for 10 to 15 minutes to obtain solution C;
[0045] (4) Vacuum evaporation of liquid C at 35°C until a gel material appears, and then continue vacuum evaporation for 10-15 min to obtain liquid D;
[0046] (5) Shake solution D on a mixer to obtain solution E;
[0047] (6) Continue to evaporate solution E under reduced pressure for 5 to 10 minutes; use dialysis to remove the organic solvent with 50 ml of buffer to obtain solution F;
[0048] (7) Liquid F was diluted to 100 ml with buffer solution, homogenized twice at 300-400 bar in a high-pressure homogenizer, and then passed through a 0.2 μm polycarbonate membrane under high pressure to obtain a sterile tyvalocin injection solution.
[0049] Example 2
[0050] A tyvalosin injection, wherein each 100 ml of the tyvalosin injection contains the following components and dosages: 20 g of tyvalosin, 13 g of dimyristoylphosphatidylcholine, 5 g of cholesterol, and the remainder is a buffer solution.
[0051] The buffer is a phosphate buffer with a pH of 7.4 containing polyethylene glycol 400, and the buffer further contains glucose, wherein the volume of polyethylene glycol 400 accounts for 10% of the total volume of the buffer, and the volume mass ratio of the buffer to glucose is 100:5 (ml:g).
[0052] The preparation method of the tyvalocin injection comprises the following steps:
[0053] (1) Add tyvalosin, dimyristoylphosphatidylcholine and cholesterol according to the formula amount into 150 ml of isopropyl ether, dissolve and clarify, and evaporate under reduced pressure at 35° C. to obtain lipid film A;
[0054] (2) Add 150 ml of isopropyl ether to lipid film A to redissolve lipid film A, and add 30 ml of buffer to obtain solution B;
[0055] (3) Ultrasonicate solution B at 4°C to 8°C for 10 to 15 minutes to obtain solution C;
[0056] (4) Vacuum evaporation of liquid C at 35°C until a gel material appears, and then continue vacuum evaporation for 10-15 min to obtain liquid D;
[0057] (5) Shake solution D on a mixer to obtain solution E;
[0058] (6) Continue to evaporate solution E under reduced pressure for 5 to 10 minutes; use dialysis to remove the organic solvent with 50 ml of buffer to obtain solution F;
[0059] (7) Liquid F was diluted to 100 ml with buffer solution, homogenized twice at 300-400 bar in a high-pressure homogenizer, and then passed through a 0.2 μm polycarbonate membrane under high pressure to obtain a sterile tyvalocin injection solution.
[0060] Example 3
[0061] A tyvalosin injection, wherein each component and dosage of the tyvalosin injection in 90 ml is as follows: 18 g of tyvalosin, 10 g of dimyristoylphosphatidylcholine, 3 g of cholesterol, and the remainder is a buffer solution.
[0062] The buffer is a pH 7.4 phosphate buffer containing polyethylene glycol 400, and the buffer further contains lactose, wherein the volume of polyethylene glycol 400 accounts for 8% of the total volume of the buffer, and the volume mass ratio of the buffer to lactose is 100:5 (ml:g).
[0063] The preparation method of the tyvalocin injection comprises the following steps:
[0064] (1) Add tyvalosin, dimyristoylphosphatidylcholine and cholesterol according to the formula amount into 120 ml of isopropyl ether, dissolve and clarify, and evaporate under reduced pressure at 40° C. to obtain lipid film A;
[0065] (2) Add 120 ml of isopropyl ether to lipid film A to redissolve lipid film A, and add 25 ml of buffer to obtain solution B;
[0066] (3) Ultrasonicate solution B at 4°C to 8°C for 10 to 15 minutes to obtain solution C;
[0067] (4) Vacuum evaporation of liquid C at 35°C until a gel material appears, and then continue vacuum evaporation for 10-15 min to obtain liquid D;
[0068] (5) Shake solution D on a mixer to obtain solution E;
[0069] (6) Continue to evaporate solution E under reduced pressure for 5 to 10 minutes; use 45 ml of buffer to remove the organic solvent by dialysis to obtain solution F;
[0070] (7) Liquid F was made up to 90 ml with buffer solution, homogenized twice at 300-400 bar in a high-pressure homogenizer, and then passed through a 0.2 μm polycarbonate membrane under high pressure to obtain a sterile tyvalocin injection solution.
[0071] Example 4
[0072] A tyvalosin injection, wherein each 110 ml of the tyvalosin injection comprises the following components and dosages: 22 g of tyvalosin, 15 g of dimyristoylphosphatidylcholine, 8 g of cholesterol, and the remainder being a buffer solution.
[0073] The buffer is a phosphate buffer with a pH of 7.4 containing polyethylene glycol 400, and the buffer further contains mannitol, glucose and lactose. The volume of polyethylene glycol 400 is 11% of the total volume of the buffer, and the volume mass ratio of the buffer to mannitol, glucose and lactose is 100:1:2.5:2.5 (ml:g:g:g).
[0074] The preparation method of the tyvalocin injection comprises the following steps:
[0075] (1) Add tyvalosin, dimyristoylphosphatidylcholine and cholesterol according to the formula amount into 180 ml of isopropyl ether, dissolve and clarify, and evaporate under reduced pressure at 35° C. to obtain lipid film A;
[0076] (2) Add 180 ml of isopropyl ether to lipid film A to redissolve lipid film A, and add 35 ml of buffer to obtain solution B;
[0077] (3) Ultrasonicate solution B at 4°C to 8°C for 10 to 15 minutes to obtain solution C;
[0078] (4) Vacuum evaporation of liquid C at 35°C until a gel material appears, and then continue vacuum evaporation for 10-15 min to obtain liquid D;
[0079] (5) Shake solution D on a mixer to obtain solution E;
[0080] (6) Continue to evaporate solution E under reduced pressure for 5 to 10 minutes; use dialysis to remove the organic solvent with 55 ml of buffer to obtain solution F;
[0081] (7) Liquid F was diluted to 110 ml with buffer solution, homogenized twice at 300-400 bar in a high-pressure homogenizer, and then passed through a 0.2 μm polycarbonate membrane under high pressure to obtain a sterile tyvalocin injection solution.
[0082] Example 5
[0083] A tyvalosin injection, wherein each 100 ml of the tyvalosin injection contains the following components and dosages: 20 g of tyvalosin, 15 g of dimyristoylphosphatidylcholine, 8 g of cholesterol, and the balance is buffer.
[0084] The buffer is a phosphate buffer with a pH of 7.4 containing polyethylene glycol 400, and the buffer further contains mannitol and glucose. The volume of polyethylene glycol 400 is 10% of the total volume of the buffer, and the volume mass ratio of the buffer to mannitol and glucose is 100:1:3 (ml:g:g).
[0085] The preparation method of the tyvalocin injection comprises the following steps:
[0086] (1) Add tyvalosin, dimyristoylphosphatidylcholine and cholesterol according to the formula amount into 180 ml of acetone, dissolve and clarify, and evaporate under reduced pressure at 35° C. to obtain lipid film A;
[0087] (2) Add 180 ml of acetone to lipid film A to redissolve lipid film A, and add 30 ml of buffer to obtain solution B;
[0088] (3) Ultrasonicate solution B at 4°C to 8°C for 10 to 15 minutes to obtain solution C;
[0089] (4) Vacuum evaporation of liquid C at 35°C until a gel material appears, and then continue vacuum evaporation for 10-15 min to obtain liquid D;
[0090] (5) Shake solution D on a mixer to obtain solution E;
[0091] (6) Continue to evaporate solution E under reduced pressure for 5 to 10 minutes; use dialysis to remove the organic solvent with 50 ml of buffer to obtain solution F;
[0092] (7) Liquid F was diluted to 100 ml with buffer solution, homogenized twice at 300-400 bar in a high-pressure homogenizer, and then passed through a 0.2 μm polycarbonate membrane under high pressure to obtain a sterile tyvalocin injection solution.
[0093] Example 6
[0094] A tyvalosin injection, wherein the components and dosages of each 100 ml of the tyvalosin injection are: 20 g of tyvalosin, 15 g of soy lecithin, 8 g of cholesterol, and the remainder is a buffer. The composition and preparation method of the buffer are substantially the same as those of Example 2.
[0095] Example 7 Test of the content of tyvalosin in the present invention
[0096] The tyvalosin injections of Examples 1-6 were tested for tyvalosin content. The test results are shown in Table 1.
[0097] Table 1 Content test results
[0098]
[0099] Note: Recovery rate* refers to the ratio of the input amount to the actual test result.
[0100] The results show that the tyvalosin injections prepared in Examples 1-5 all achieved successful detection of tyvalosin, and the content recovery rates were all greater than 90%, especially Examples 2, 3, 4, and 5 had higher recovery rates, but the sample recovery rate prepared in Example 6 was lower, less than 90%, which was related to the encapsulation rate of the samples. The encapsulation rates of Examples 2 to 5 were higher, and the encapsulation rate of Example 6 was lower.
[0101] Example 8 Pharmacokinetics of Tylvalosin Injection of the Present Invention
[0102] Test method:
[0103] 1. Experimental animals: Six Duchangda hybrid pigs with an average weight of 20 kg were randomly divided into two groups, namely the experimental group and the control group.
[0104] 2. Dosage scheme: The test group was injected with the tyvalosin injection prepared in Example 2, and the control group was injected with the tyvalosin injection prepared by dissolving the tyvalosin raw material in 10% N,N-diformylacetamide. Each group was dosed at 5 mg / kg bw. Blood was collected from the anterior vena cava at 0h, 0.167h, 0.5h, 0.75h, 1h, 1.5h, 2h, 4h, 6h, 8h, 10h, 12h, 16h, 20h, 24h, 30h, 36h, 42h, 48h, 60h, and 72h, and then processed and analyzed to determine the content of tyvalosin in the blood samples at different time points.
[0105] 3. Experimental results and analysis
[0106] After blood was collected at different time points, the results of the test for the content of tyvalosin in the plasma of each group of pigs and the main pharmacokinetic parameters are shown in Table 2 and Table 3. The drug-time curves of the pharmacokinetic test results are shown in Figure 1 .
[0107] Table 2 Plasma tyvalosin content in each group of pigs at different times (X, μg / mL)
[0108] Time Experimental Group Control group 0 0.00 0 0.167 0.64 0.36 0.5 0.76 1.43 0.75 1.30 2.17 1 1.40 2.76 1.5 1.73 2.27 2 1.90 1.85 4 1.81 1.54 6 1.59 0.78 8 1.51 0.64 10 1.40 0.42 12 1.08 0.32 16 0.84 0.30 20 0.52 0.27 24 0.46 0.24 30 0.30 0.22 36 0.27 0.19 42 0.24 0.15 48 0.22 0.12 60 0.19 ND 72 0.15 ND
[0109] Note: “ND” stands for not detected.
[0110] Table 3 Main pharmacokinetic parameters of tyvalosin in each group
[0111] parameter unit Experimental Group Control group Cmax μg / mL 1.90 2.76 Tmax h 2.0 1.0 Relative bioavailability % 186.26% /
[0112] The results of pharmacokinetic tests show that the bioavailability of the tyvalosin injection prepared by the present invention is 1.86 times that of the tyvalosin injection prepared by dissolving the tyvalosin raw material in 10% N,N-diformylacetamide, which is significantly superior to the common tyvalosin injection.
[0113] Example 9 Clinical effect test of tyvalosin injection of the present invention
[0114] Test method:
[0115] 1. Experimental animals: Animals with clinical respiratory diseases, manifested by body temperature above 40.5℃, increased respiratory rate, and poor condition, were selected. They were Duroc-Changda hybrid pigs weighing 30-50kg. A total of 90 pigs were randomly divided into three groups, namely the experimental group, control group 1, and control group 2.
[0116] 2. Dosage scheme: The test group was injected with the tyvalosin injection prepared in Example 2, the control group 1 was injected with the drug prepared in patent CN102119921A (Example 2), and the control group 2 was injected with the drug prepared in patent CN108403631A (Example 1). Each group was administered at 7 mg / kg bw, once, and the cure rate and mortality rate were observed 7 days after the end of the administration. The criteria for cure were that the body temperature dropped to within 40°C, the breathing returned to normal, and the mental state returned to normal.
[0117] 3. Experimental results and analysis
[0118] After the administration, the animals were observed for 7 days. The cure rates of the animals in each group are shown in Table 4 below.
[0119] Table 4 Statistics of therapeutic effects of different groups of experimental animals
[0120] Group Experimental Group Control group 1 Control group 2 Number of experimental animals 30 30 30 Number of cured heads 25 15 18 Number of deaths 0 2 1 Cure rate 83.3% 50.0% 60.0% mortality rate 0% 6.67% 3.33%
[0121] The results in Table 4 show that the cure rates of different groups of drugs in the treatment of porcine respiratory diseases are significantly different, among which the cure rate of the test group is higher, reaching more than 80%, while the cure rate of the control group 2 is only 60%, and the control group 1 is even only 50%. It can be seen that under the current treatment method, a single injection of 7mg / kgbw of tyvalocin has a good therapeutic effect in the test group, while the therapeutic effects of the two control groups are not good, which may be because the blood drug maintenance time of the control group is shorter, and the drug concentration cannot be well maintained in the body after a single administration, and the therapeutic effect cannot be achieved.
[0122] The present invention is not limited to the above-mentioned embodiments. Without departing from the principle and scope of the present invention, the present invention may also have other changes and improvements.
Claims
1. A tyvalocin injection, characterized in that: The tyvalosin injection is composed of the following components: tyvalosin, dimyristoylphosphatidylcholine, cholesterol and buffer.
2. The tyvalocin injection according to claim 1, characterized in that: The mass ratio of tyvalosin, dimyristoylphosphatidylcholine and cholesterol in the tyvalosin injection is (18-22):(10-15):(3-8).
3. The tyvalocin injection according to claim 1, characterized in that: The buffer is a phosphate buffer at pH 7.4 containing polyethylene glycol 400.
4. The tyvalocin injection according to claim 3, characterized in that: The buffer solution also contains one or more of mannitol, glucose and lactose.
5. The tyvalocin injection according to claim 3, characterized in that: The amount of polyethylene glycol 400 used is 8% to 12% of the total volume of the buffer solution.
6. A method for preparing a tyvalocin injection as claimed in any one of claims 1 to 5, comprising the following steps: (1) adding tyvalosin, dimyristoylphosphatidylcholine and cholesterol according to the formula amount into an organic solvent, dissolving and clarifying, and then evaporating under reduced pressure to obtain a lipid film A; (2) adding an organic solvent to redissolve the lipid film A, and adding a buffer to obtain solution B; (3) Ultrasonicate solution B at 4°C to 8°C for 10 to 15 minutes to obtain solution C; (4) Vacuum evaporation of liquid C until a gel material appears, and then continue vacuum evaporation for 10 to 15 minutes to obtain liquid D; (5) Shake solution D on a mixer to obtain solution E; (6) Continue to perform vacuum rotary evaporation on solution E for 5 to 10 minutes; use dialysis to remove the organic solvent with a buffer solution to obtain solution F; (7) Solution F was diluted to a certain volume with a buffer solution, homogenized twice at 300-400 bar in a high-pressure homogenizer, and then passed through a 0.2 μm polycarbonate membrane under high pressure to obtain a sterile tyvalocin injection solution.
7. The preparation method according to claim 6, characterized in that: The organic solvent in step (1) and step (2) is one or more of ethanol, isopropanol, ether, isopropyl ether, acetone, and chloroform, and the volume mass ratio of the added amount of the organic solvent to the tyvalocin is (120-180):(18-22).
8. The preparation method according to claim 6, characterized in that: The temperature of the reduced pressure rotary evaporation in steps (1), (4) and (6) is 30 to 40°C.
9. The preparation method according to claim 6, characterized in that: The volume mass ratio of the amount of the buffer added in step (2) to tyvalocin is (25-35):(18-22).
10. The preparation method according to claim 6, characterized in that: The volume mass ratio of the amount of buffer added to tyvalocin in step (6) is (45-55):(18-22).
